• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

oculartherapeutix

Conventus Ortho taps Epstein as CEO | Personnel Moves – June 5, 2019

June 5, 2019 By Fink Densford

Conventus Orthopaedics said today that it named Rick Epstein as its new chief executive officer and board member. The Minneapolis-based company said that Epstein has more than 30 years in executive leadership roles, having previously served as chief executive officer for Omni Life Sciences. “Rick has a track record of accelerating businesses through a focus […]

Filed Under: Business/Financial News Tagged With: caresyntax, CeQur Ltd., Check-Cap, Conventus Orthopaedics, Dynatronics Corp, electroCore, endralifesciences, oculartherapeutix, Outset Medical, Personnel Moves

Ocular Therapeutix touts Medicare reimbursement win

May 29, 2019 By Fink Densford

Ocular Therapeutix (NSDQ:OCUL) said today that the Centers for Medicare and Medicaid Services approved a transitional pass-through payment status and established a new reimbursement C-code for its Dextenza device. The Bedford, Mass.-based company’s Dextenza device is designed to deliver drugs for up to 30 days following treatment in a physician’s office. Ocular Therapeutix is positioning its […]

Filed Under: Business/Financial News, Optical/Ophthalmic Tagged With: oculartherapeutix

Ocular Therapeutix OTX-TP trial misses primary endpoint

May 22, 2019 By Danielle Kirsh

A Phase 3 clinical trial of the ORX-TP eye insert made by Ocular Therapeutix (NSDQ:OCUL) failed to meet the primary endpoint of significant superiority in the reduction of intraocular pressure. OTX-TP is an intracanalicular insert that delivers a preservative-free formulation of travoprost to reduce intraocular pressure. The randomized, double-blind, placebo-controlled clinical trial took place across more […]

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic Tagged With: oculartherapeutix

‘Berkmorgazon’ health play Haven COO Stoddard steps away | Personnel Moves – May 17, 2019

May 17, 2019 By Fink Densford

Healthcare joint venture Haven, started by Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan, has lost its COO Jack Stoddard at just nine months post-hiring, according to a CNBC report. The former digital health general manager for Comcast told the news channel that he is departing the healthcare play due to personal reasons, including the distance between […]

Filed Under: Business/Financial News Tagged With: Amazon, avitamedical, Berkshire Hathaway, Boston Scientific, Cantel Medical Corp., Fresenius, gerresheimer, haven, JP Morgan Chase, oculartherapeutix, proteor, Pulmatrix Inc.

Ocular Therapeutix escapes SEC probe

May 13, 2019 By Danielle Kirsh

The SEC recently closed its probe into Ocular Therapeutix (NSDQ:OCUL) and found no wrongdoing in the investigation. Ocular Therapeutix received a subpoena from the SEC on Dec. 15, 2017, for documents and information pertaining to its Dextenza 0.4mg and related communication with the FDA, investors and other parties. The company received a second subpoena on Aug. 21, […]

Filed Under: Legal News Tagged With: oculartherapeutix

Ocular Therapeutix posts wider-than-forecast Q1 losses

May 10, 2019 By Danielle Kirsh

Ocular Therapeutix (NSDQ:OCUL) posted first-quarter results today that were wider than the consensus on Wall Street, missing the earnings consensus and beating on revenue. The Bedford, Mass.-based company reported losses of -$17.1 million, or -45¢ per share, on sales of $492,000 for the three months ended March 31, widening its losses by 24.4% on sales growth […]

Filed Under: Wall Street Beat Tagged With: oculartherapeutix

Ocular Therapeutix settles Mati Therapeutics patent spat, logs CMS win for Dextenza

May 1, 2019 By Fink Densford

Ocular Therapeutix (NSDQ:OCUL) said this week it settled a patent spat with Mati Therapeutics and that it won reimbursement from the Centers for Medicare and Medicaid Services for its Dextenza ocular insert. In an SEC filing posted yesterday, the Bedford, Mass.-based company said that it settled its litigation with Mati Therapeutics and that both parties dismissed […]

Filed Under: Business/Financial News, Legal News, Optical/Ophthalmic, Patent Infringement Tagged With: oculartherapeutix

FDA accepts second application for Ocular Therapeutix’s drug-delivering implant

April 3, 2019 By Fink Densford

Ocular Therapeutix (NSDQ:OCUL) said today that the FDA has accepted a new supplemental New Drug Application for its Dextenza, an ocular insert designed to release dexamethasone to relieve pain following ophthalmic surgery. The Bedford, Mass.-based company’s device is designed to deliver drugs for up to 30 days following treatment in a physician’s office. Ocular Therapeutix is […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance Tagged With: oculartherapeutix

Ocular Therapeutix posts mixed Q4 results

March 8, 2019 By Sarah Faulkner

Shares in Ocular Therapeutix (NSDQ:OCUL) fell in premarket activity today after the company posted mixed fourth-quarter results. The Bedford, Mass.-based company posted a net loss of -$17.4 million, or -42¢ per share, on sales of $504,000 for the three months ended Dec. 31, for sales growth of 3.5% compared with the same period last year. Get the […]

Filed Under: Business/Financial News, Drug-Device Combinations, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: oculartherapeutix

Ocular Therapeutix inks $38m debt financing deal

February 22, 2019 By Sarah Faulkner

Ocular Therapeutix (NSDQ:OCUL) said today that it inked a deal with an investor to issue $37.5 million in 6% subordinated convertible notes due 2026. The offering is slated to close on March 1, according to the Bedford, Mass.-based company. Ocular expects to reel in roughly $37.1 million in net proceeds from the offering, which it plans […]

Filed Under: Business/Financial News, Drug-Device Combinations, Funding Roundup, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: oculartherapeutix

Ocular Therapeutix doses first wet-AMD patient in implant trial

February 20, 2019 By Sarah Faulkner

Ocular Therapeutix (NSDQ:OCUL) said today that it dosed the first patient in a study of its OTX-TKI tyrosine kinase inhibitor implant. The Phase I trial is slated to assess the bioresorbable device’s safety, durability and tolerability in people with wet age-related macular degeneration. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: oculartherapeutix

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 9
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS